Clorox (NYSE:CLX) Price Target Cut to $117.00 by Analysts at TD Cowen

Key Points

• TD Cowen has cut Clorox's price target from $120.00 to $117.00, suggesting a potential downside of 4.06% from its current price, while maintaining a "hold" rating.
• Clorox's recent quarterly earnings report showed an EPS of $2.87, exceeding estimates, with a revenue increase of 4.5% year-over-year.
• Currently, the stock has a consensus rating of "Reduce," with one Buy, nine Holds, and three Sell ratings from analysts.

Clorox (NYSE:CLX - Get Free Report) had its price target reduced by research analysts at TD Cowen from $120.00 to $117.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The firm presently has a "hold" rating on the stock. TD Cowen's price target suggests a potential downside of 4.06% from the stock's current price.

A number of other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Clorox from $133.00 to $135.00 and gave the stock a "neutral" rating in a report on Monday, September 8th. Morgan Stanley reduced their price objective on Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Jefferies Financial Group dropped their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Wells Fargo & Company lowered their price target on Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a research note on Thursday, September 25th. Finally, Barclays reduced their target price on Clorox from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Clorox currently has a consensus rating of "Reduce" and a consensus target price of $134.08.

Clorox Price Performance

Shares of NYSE:CLX traded down $1.36 on Wednesday, hitting $121.95. The company had a trading volume of 63,258 shares, compared to its average volume of 1,682,647. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. Clorox has a 52-week low of $116.53 and a 52-week high of $171.37. The business has a 50 day moving average of $123.33 and a 200 day moving average of $130.02. The company has a market cap of $14.92 billion, a PE ratio of 18.76, a PEG ratio of 0.99 and a beta of 0.52.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period in the prior year, the firm posted $1.82 earnings per share. The firm's revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities analysts anticipate that Clorox will post 7.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the transaction, the chief operating officer directly owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Clorox

A number of large investors have recently modified their holdings of CLX. Wellington Management Group LLP lifted its position in Clorox by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 4,074 shares of the company's stock valued at $662,000 after acquiring an additional 646 shares during the period. Fifth Third Wealth Advisors LLC lifted its position in Clorox by 36.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,712 shares of the company's stock valued at $252,000 after acquiring an additional 457 shares during the period. Rhumbline Advisers lifted its position in Clorox by 5.7% during the 1st quarter. Rhumbline Advisers now owns 273,462 shares of the company's stock valued at $40,267,000 after acquiring an additional 14,647 shares during the period. Czech National Bank raised its holdings in Clorox by 5.4% in the first quarter. Czech National Bank now owns 28,294 shares of the company's stock worth $4,166,000 after buying an additional 1,455 shares during the last quarter. Finally, NBC Securities Inc. raised its holdings in Clorox by 123,850.0% in the first quarter. NBC Securities Inc. now owns 2,479 shares of the company's stock worth $365,000 after buying an additional 2,477 shares during the last quarter. Institutional investors own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.